학술논문

Genome-wide association study of corticobasal degeneration identifies risk variants shared with progressive supranuclear palsy.
Document Type
article
Source
Nature communications. 6(1)
Subject
Cerebral Cortex
Humans
Basal Ganglia Diseases
Supranuclear Palsy
Progressive
Neurodegenerative Diseases
Kinesin
SOS1 Protein
tau Proteins
Myelin Proteins
Case-Control Studies
Polymorphism
Single Nucleotide
Adult
Aged
Aged
80 and over
Middle Aged
Female
Male
Genome-Wide Association Study
Young Adult
RNA
Long Noncoding
and over
Polymorphism
Single Nucleotide
RNA
Long Noncoding
Supranuclear Palsy
Progressive
Language
Abstract
Corticobasal degeneration (CBD) is a neurodegenerative disorder affecting movement and cognition, definitively diagnosed only at autopsy. Here, we conduct a genome-wide association study (GWAS) in CBD cases (n=152) and 3,311 controls, and 67 CBD cases and 439 controls in a replication stage. Associations with meta-analysis were 17q21 at MAPT (P=1.42 × 10(-12)), 8p12 at lnc-KIF13B-1, a long non-coding RNA (rs643472; P=3.41 × 10(-8)), and 2p22 at SOS1 (rs963731; P=1.76 × 10(-7)). Testing for association of CBD with top progressive supranuclear palsy (PSP) GWAS single-nucleotide polymorphisms (SNPs) identified associations at MOBP (3p22; rs1768208; P=2.07 × 10(-7)) and MAPT H1c (17q21; rs242557; P=7.91 × 10(-6)). We previously reported SNP/transcript level associations with rs8070723/MAPT, rs242557/MAPT, and rs1768208/MOBP and herein identified association with rs963731/SOS1. We identify new CBD susceptibility loci and show that CBD and PSP share a genetic risk factor other than MAPT at 3p22 MOBP (myelin-associated oligodendrocyte basic protein).